Latest News on FOP
Regeneron Publishes Peer-Reviewed Results of Phase 2 LUMINA-1 Clinical Trial
On September 28, 2023, Regeneron published the results of their Phase 2 LUMINA-1 Clinical Trial of the drug garetosmab in Nature Medicine, a peer-reviewed publication. Regeneron also published clinical pharmacology results from the LUMINA-1 Trial in...
35 Years Later, FOP Connection Continues Bringing the Community Together
From a readership of 11 in 1988 to more than 2,000 in 2023, the IFOPA newsletter has evolved to inform and connect friends across the world Together with her sister-in-law, Anne, and fellow IFOPA founding member, Nancy Sando, Jeannie Peeper published the first edition...
‘This Assistance Has Been Life-Changing’
L.I.F.E. Award Grant makes it easier for professional with FOP to work from home Kathleen Degenhardt works from home. She also has FOP, which makes it difficult for her to perform some tasks. She learned about the Harold & Elaine Kaplan Quality of L.I.F.E....
What’s New with In Pursuit of a Cure 2023?
Connect with FOP researchers, meet new families and more! You'll notice a few things are brand new for this year's In Pursuit of a Cure campaign. But the most important part of the campaign is the same — you! Read on for a quick update on...
Clementia Granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans Progressiva
MONTREAL, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that the U.S. Food and Drug...
Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 Results
NDA Submission Planned for the Second Half of 2019 MONTREAL, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases,...
Blueprint Medicines Presents Foundational Preclinical Data Supporting the Development of BLU-782, a Highly Selective ALK2 Inhibitor, for the Treatment of Patients with Fibrodysplasia Ossificans Progressiva
Blueprint Medicines Corporation, a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced preclinical proof-of-concept data for BLU-782, an investigational oral precision therapy specifically...
Clementia Announces Updated Phase 2 Part B Data on Palovarotene for FOP
Clementia Pharmaceuticals Inc., a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced updated data from the open label extension (“Part B”) of its ongoing Phase 2 clinical trial...
Human skeletal stem cells identified
Human skeletal stem cells that become bone, cartilage, or stroma cells have been isolated from fetal and adult bones. This is the first time that skeletal stem cells, which had been observed in rodent models, have been identified in humans. The researchers were also...
Regeneron’s LUMINA-1 Trial hosted by FOP Friends
Learn more about Regeneron's LUMINA-1 clinical trial presented by Dr. Richard Keen from the Royal National Orthopaedic Hospital in England. This webinar is hosted by FOP Friends in the United Kingdom http://fopfriends.com/. Source: FOPnews